Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Neoplasm Metastasis × olaparib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 7 OTHER 4 NIH 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Thymoma 1 Sarcoma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Mesothelioma 1 Lung Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Irinotecan 6 S 1 (combination) 4 Oxaliplatin 3 palbociclib 2 durvalumab 2 Tamoxifen 2 Radiation 2 Erlotinib Hydrochloride 2 Cetuximab 2 Capecitabine 2 tremelimumab 1 trametinib 1 titanium silicide 1 sintilimab 1 olaparib 1 nilotinib 1 glasdegib 1 genexol-PM 1 futibatinib 1 dabrafenib 1 ceritinib 1 capmatinib 1 anlotinib 1 Temozolomide 1 Talc 1 Surgical Procedures, Operative 1 Radiosurgery 1 Paclitaxel 1 Methylene Blue 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03784014 2025-12-11

MULTISARC

Institut National de la Santé Et de la Recherche Médicale, France

Phase 3 Active not recruiting

Neoplasm Metastasis, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡